FDA Approves Fourth Ustekinumab Biosimilar
The U.S. Food and Drug Administration (FDA) has approved Otulfi, an ustekinumab biosimilar referencing Stelara, from Fresenius Kabi and Formycon AG. Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23. Otulfi is approved for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis. This […]